Replagal FDA Approval Status
FDA Approved: No
Brand name: Replagal
Generic name: agalsidase alfa
Company: Shire plc
Treatment for: Fabry Disease
Replagal (agalsidase alfa) is an enzyme replacement therapy in development for Fabry disease.
Development timeline for Replagal
| Date | Article |
|---|---|
| Dec 22, 2009 | Shire Submits Biologics License Application for Replagal With the U.S. Food and Drug Administration |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
